JPRN-UMIN000007140招募中2 期
Multicenter Phase II Study of the Safety and Efficacy of Nilotinib in Patients with Chronic Phase Chronic Myelogenous Leukemia Showing a Major Molecular Response to Imatinib - Switch to Nilotinib trial (NILSw trial)
Cooperative study between the West Japan Hematology Study Group and the Clinical Research Support Center Kyushu0 个研究点目标入组 130 人开始时间: 2012年2月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 130
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 16years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients previously treated by tyrosine kinase inhibitors other than imatinib. 2) Patients confirmed to have the T315I point mutation of BCR-ABL. 3) Patients with a history of hematopoietic stem cell transplantation. 4) Patients with cardiovascular dysfunction. 5) Pregnant women or those with suspected pregnancy. Nursing women and those who plan to become pregnant during the study period.
研究者
相似试验
进行中（未招募）
不适用
A Phase 2 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Chronic Hidradenitis SuppurativaHidradenitis Suppurativa (HS) is a painful, chronic, skin disease characterized by recurrent inflamed nodules, abscesses, and fistulas, which may heal with scarring. The most commonly involved anatomic locations are the inguino-crural and axillary folds, with sub-mammary folds (in women) and the perineal area less commonly involved.MedDRA version: 9.1Level: LLTClassification code 10020041Term: Hidradenitis suppurativaEUCTR2008-004587-38-DKAbbott GmbH & Co. KG150
进行中（未招募）
不适用
A Phase 2 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Chronic Hidradenitis SuppurativaHidradenitis Suppurativa (HS) is a painful, chronic, skin disease characterized by recurrent inflamed nodules, abscesses, and fistulas, which may heal with scarring. The most commonly involved anatomic locations are the inguino-crural and axillary folds, with sub-mammary folds (in women) and the perineal area less commonly involved.MedDRA version: 9.1Level: LLTClassification code 10020041Term: Hidradenitis suppurativaEUCTR2008-004587-38-NLAbbott GmbH & Co. KG150
进行中（未招募）
不适用
A Phase 2 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Chronic Hidradenitis SuppurativaEUCTR2008-004587-38-DEAbbott GmbH & Co. KG150
招募中
2 期
IPD-MM22 studyewly-diagnosed multiple myelomaJPRN-jRCT2011230049Goto Hideki55
已完成
2 期
Multicenter Phase II Clinical Study of the Safety and Efficacy of Discontinuing Nilotinib Treatment in Patients with Chronic Phase Chronic Myelogenous Leukemia Who Have Achieved Complete Molecular Response with Imatinib or NilotinibChronic Myelogenenous LeukemiaJPRN-UMIN000007141Cooperative study between the West Japan Hematology Study Group and the Clinical Research Support Center Kyushu120